Skip to main content

Antimicrobial Resistance Issues and Options (1998) / Chapter Skim
Currently Skimming:

Appendix D: Workshop Agenda
Pages 112-115

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 112...
... A FIRST LOOK AT THE COSTS OF ANTIMICROBIAL RESISTANCE Robert Rubin, The Lewin Group 9:30 TRACKING THE PROBLEM: APPROACHES TO SURVEILLANCE AND WHAT IS NEEDED An Overview David Bell, CDC The Global Perspective David Heymann, WHO A National Model Donald Low, Canada A Network for Research Karl Kristinsson, GEM/NET A U.S. State Perspective Michael Osterholm, Minnesota Department of Health 112
Read the entire page →
From page 113...
... High-Density Oligonucleotide Arrays Tom Gingeras, Affymetrix Applications of Genomics/Bioinformatics to Development of Anti-Infectives George Miller, Schering-Plough Research Institute A Role for New Therapeutic Approaches in Combating Antimicrobial Resistance Mich Hein, EPIcyte Applications of Field Surveillance (U.S. and International)
Read the entire page →
From page 114...
... Department of Agriculture Bob Buchanan, USDA/ARS/ERRC Kaye Wachsmuth, USDA/FSI Concerns and Perspectives from the U.S. Environmental Protection Agency Mark Wilhite, EPA 4:45 DISCUSSION ADJOURN THURSDAY, JULY 31 8:30 OTHER CONCERNS AND MECHANISMS OF RESPONSE Legal Issues Arising from Development of Antimicrobial Resistance David Fidler, University of Indiana Expired Patents and the Potential of Existing Compounds Discussants: Gerald Mossinghoff, George Washington School of Law Vincent Ahonkhai, SmithKline Beecham Restricted Dist~budon and the Market General Discussion with FDA participants as resources , These topics surfaced in the first forum workshop on February 10-11, 1997, which was entitled "Orphans and Incentives: Developing Technologies for Emerging Infections." They were sufficiently provocative for us to feel that they merited further discussion to see what, if any, potential they might hold for stimulating new R&D and, in particular, dealing with antimicrobial resistance.
Read the entire page →
From page 115...
... APPENDIX D - 1 1 5 Orphan Drug Act Update: Looking Through the Prism of Staphylococcus aureus in Japan Discussants: Fred Tenover, CDC Mark Goldberger, FDA 10:00 GENERAL DISCUSSION: REVISITING YESTERDAY'S TOPICS AND EXTRACTING TAKEAWAY LESSONS, ISSUES, AND NEXT STEPS 11:00 ADJOURNMENT
Read the entire page →

Key Terms

  • emerging infections
  • sufficiently provocative
  • vincent ahonkhai
  • fda experts
  • craig venter

  • developing technologies
  • gerald mossinghoff
  • michael osterholm
  • legal issues
  • please note

  • genes associated
  • david relman
  • therapeutic approaches
  • michael marcy
  • formally listed

  • minnesota department
  • smithkline beecham
  • answer questions
  • washington school
  • genomic research

  • combating antimicrobial
  • kaiser permanente
  • molecular detection
  • stuart levy
  • thomas quinn

  • issues arising
  • specific fields
  • george miller
  • resistance david
  • research institute


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.